MedTrace Logo

Inpatient Group Acceptance and Commitment Therapy (ACT) for Psychosis Spectrum Disorder

NCT06086184 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2023-11-18

No results posted yet for this study

Summary

The pilot study that will serve as the basis for the larger project - a multicenter randomized controlled single-blinded trial (RCT) will focus on testing the feasibility and efficacy of an inpatient group ACT treatment program and its effects on symptom severity and patient satisfaction in patients with psychosis spectrum disorder. The ACT-specific treatment program for inpatients with psychosis spectrum disorder is designed to enable patients to deal with their disease in an accepting manner over the long term, to promote self-determined and positive attitudes toward treatment and support options, and thus to reduce rehospitalization rates.

Conditions

  • Psychotic Disorders
  • Acceptance and Commitment Therapy
  • Psychotherapy, Group
  • Inpatients

Interventions

BEHAVIORAL

ACT group therapy

Participation in four sessions of the inpatient "Compass Group" and eight sessions of the inpatient "Here-and-Now Group". This should be completed within four weeks and may be completed within six weeks in exceptional cases. The groups are designed as a semi-open group with one therapist and one cotherapist each and are integrated into the existing therapy plan.

Sponsors & Collaborators

  • Vivantes Netzwerk für Gesundheit GmbH

    lead OTHER

Principal Investigators

  • Andreas Bechdolf, Prof. Dr. · Senior consultant department of psychiatry Vivantes Klinikum Am Urban and Klinikum im Friedrichshain

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-16
Primary Completion
2025-02-28
Completion
2025-02-28

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06086184 on ClinicalTrials.gov